Finance

Beta
Lists
DNA:NYSE
Ginkgo Bioworks Holdings Inc
$9.35
+7.10%
(+0.62) 1D
Jun 4, 2:35:24 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNA...
Open
$8.54
High
$10.53
Low
$8.51
Mkt. cap
582.73M
Avg. vol.
1.28M
Volume
3.20M
52-wk high
$17.58
52-wk low
$5.37
EPS
-$5.35
Beta
1.79
Shares outstanding
53.36M
No. of employees
485
Open
$8.54
High
$10.53
Low
$8.51
Mkt. cap
582.73M
Avg. vol.
1.28M
Volume
3.20M
52-wk high
$17.58
52-wk low
$5.37
EPS
-$5.35
Beta
1.79
Shares outstanding
53.36M
No. of employees
485
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to DNA in the past 3 months
Sell
Buy
1
Hold
0
Sell
2
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for DNA in the last 3 months.
Highest
Current $9.35
$12.00 (+28.34%)
Average
$8.50 (-9.09%)
Lowest
$5.00 (-46.52%)
News stories
From sources across the web
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Websiteginkgo.bio
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.39 / -
0.00%miss
Revenue / Est. (USD)
19.47M / 42.96M
-54.67%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
49.60M
38.84M
33.40M
19.47M
Cost of goods sold
14.82M
12.80M
7.30M
3.10M
Cost of revenue
14.82M
12.80M
7.30M
3.10M
Research and development expenses
53.37M
69.35M
50.13M
49.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.28M
44.95M
46.01M
37.83M
Operating expense
96.65M
114.31M
96.14M
87.75M
Total operating expenses
111.47M
127.11M
103.44M
90.85M
Operating income
-61.87M
-88.27M
-70.05M
-71.37M
Other non operating income
-896.00K
-163.00K
821.00K
-388.00K
EBT including unusual items
-60.58M
-80.75M
-81.39M
-76.14M
EBT excluding unusual items
-56.68M
-82.69M
-62.01M
-68.17M
Income tax expense
-283.00K
1.00K
-643.00K
-80.00K
Effective tax rate
0.47%
-
0.79%
0.10%
Other operating expenses
-
-
-
-
Net income
-60.30M
-80.76M
-80.75M
-82.59M
Net profit margin
-121.56%
-207.93%
-241.80%
-424.09%
Earnings per share
-
-
-0.77
-
Interest and investment income
6.08M
5.74M
7.21M
3.60M
Interest expense
-
-
-
-
Net interest expenses
6.08M
5.74M
7.21M
3.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.37M
-88.10M
-61.08M
-62.78M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more